Silvia Hofer, Elisabeth Rushing, Matthias Preusser, Christine Marosi
{"title":"高级胶质瘤的分子生物学:临床医生应该知道些什么?","authors":"Silvia Hofer, Elisabeth Rushing, Matthias Preusser, Christine Marosi","doi":"10.5732/cjc.013.10218","DOIUrl":null,"url":null,"abstract":"<p><p>The current World Health Organization classification system of primary brain tumors is solely based on morphologic criteria. However, there is accumulating evidence that tumors with similar histology have distinct molecular signatures that significantly impact treatment response and survival. Recent practice-changing clinical trials have defined a role for routine assessment of O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in glioblastoma patients, especially in the elderly, and 1p and 19q codeletions in patients with anaplastic glial tumors. Recently discovered molecular alterations including mutations in IDH-1/2, epidermal growth factor receptor (EGFR), and BRAF also have the potential to become targets for future drug development. This article aims to summarize current knowledge on the molecular biology of high-grade gliomas relevant to daily practice. </p>","PeriodicalId":10034,"journal":{"name":"癌症","volume":"33 1","pages":"4-7"},"PeriodicalIF":0.0000,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f3/11/cjc-33-01-004.PMC3905084.pdf","citationCount":"26","resultStr":"{\"title\":\"Molecular biology of high-grade gliomas: what should the clinician know?\",\"authors\":\"Silvia Hofer, Elisabeth Rushing, Matthias Preusser, Christine Marosi\",\"doi\":\"10.5732/cjc.013.10218\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The current World Health Organization classification system of primary brain tumors is solely based on morphologic criteria. However, there is accumulating evidence that tumors with similar histology have distinct molecular signatures that significantly impact treatment response and survival. Recent practice-changing clinical trials have defined a role for routine assessment of O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in glioblastoma patients, especially in the elderly, and 1p and 19q codeletions in patients with anaplastic glial tumors. Recently discovered molecular alterations including mutations in IDH-1/2, epidermal growth factor receptor (EGFR), and BRAF also have the potential to become targets for future drug development. This article aims to summarize current knowledge on the molecular biology of high-grade gliomas relevant to daily practice. </p>\",\"PeriodicalId\":10034,\"journal\":{\"name\":\"癌症\",\"volume\":\"33 1\",\"pages\":\"4-7\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f3/11/cjc-33-01-004.PMC3905084.pdf\",\"citationCount\":\"26\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"癌症\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5732/cjc.013.10218\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2013/12/11 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"癌症","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5732/cjc.013.10218","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2013/12/11 0:00:00","PubModel":"Epub","JCR":"Q","JCRName":"Medicine","Score":null,"Total":0}
Molecular biology of high-grade gliomas: what should the clinician know?
The current World Health Organization classification system of primary brain tumors is solely based on morphologic criteria. However, there is accumulating evidence that tumors with similar histology have distinct molecular signatures that significantly impact treatment response and survival. Recent practice-changing clinical trials have defined a role for routine assessment of O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in glioblastoma patients, especially in the elderly, and 1p and 19q codeletions in patients with anaplastic glial tumors. Recently discovered molecular alterations including mutations in IDH-1/2, epidermal growth factor receptor (EGFR), and BRAF also have the potential to become targets for future drug development. This article aims to summarize current knowledge on the molecular biology of high-grade gliomas relevant to daily practice.
期刊介绍：
In July 2008, Landes Bioscience and Sun Yat-sen University Cancer Center began co-publishing the international, English-language version of AI ZHENG or the Chinese Journal of Cancer (CJC). CJC publishes original research, reviews, extra views, perspectives, supplements, and spotlights in all areas of cancer research. The primary criteria for publication in CJC are originality, outstanding scientific merit, and general interest. The Editorial Board is composed of members from around the world, who will strive to maintain the highest standards for excellence in order to generate a valuable resource for an international readership.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
